Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA7 | P43166 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CA3 | P07451 | 2/20 | 0.52 |
| ▸ | CA4 | P22748 | 2/20 | 0.52 |
| ▸ | CA6 | P23280 | 2/20 | 0.52 |
| ▸ | CA5A | P35218 | 2/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SELL | P14151 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4365047 | 0.84 | CA12 (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2191755 | 0.84 | ALDH1A1 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4269298 | 0.83 | CA12 (0.70) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL9064511 | 0.82 | ALDH1A1 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18593254 | 0.82 | CA5A (0.45) | LMNACA5AMAPK1MAPTTDP1 | |
| Hydrochloric Acid SCHEMBL1144809 | 0.81 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9787632 | 0.80 | CA12 (0.73) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2810884 | 0.78 | HCAR1 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1019170 | 0.78 | HDAC1 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL447702 | 0.78 | KDM4E (0.46) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183224-A1 | BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-06-15 | — | — | US | disclosed |
| EP-3724186-A1 | BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2020-10-21 | — | — | EP | disclosed |
| US-20200308158-A1 | BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-01 | — | — | US | disclosed |
| CN-111295383-A | Benzoxazine derivatives useful as monoacylglycerol lipase inhibitors | 豪夫迈·罗氏有限公司 | 2020-06-16 | — | — | CN | disclosed |
| WO-2019115660-A1 | BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-06-20 | — | — | WO | disclosed |
| US-8492370-B2 | Compounds and methods for their production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-23 | — | — | US | disclosed |
| EP-1973883-B1 | NOVEL COMPOUNDS AND METHODS FOR THEIR PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20110160175-A1 | 18,21-Didesoxymacbecin Derivatives for the Treatment of Cancer | MARTIN CHRISTINE | 2011-06-30 | — | — | US | disclosed |
| US-20110021481-A1 | Novel Compounds and Methods for Their Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | disclosed |
| WO-2008056189-A1 | 18, 21-DIDESOXYMACBECIN DERIVATIVES FOR THE TREATMENT OF CANCER | BIOTICA TECHNOLOGY LIMITED (GB) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008056188-A2 | NOVEL COMPOUNDS AND METHODS FOR THEIR PRODUCTION | BIOTICA TECHNOLOGY LIMITED (GB) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183224-A1 | BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | LPL, LIPC, PNLIP | CA12 4635/4885CA1 4730/4885CA2 3912/4885 |
| US-20200308158-A1 | BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | LPL, LIPC, PNLIP | CA12 4635/4885CA1 4730/4885CA2 3912/4885 |
| US-20110160175-A1 | 18,21-Didesoxymacbecin Derivatives for the Treatment of Cancer | BCL3, CD22, MEN1 | CA12 1666/4885CA1 3610/4885CA2 4518/4885 |
| US-20110021481-A1 | Novel Compounds and Methods for Their Production | BCL6, BCL3, AQP4 | CA12 3471/4885CA1 3205/4885CA2 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.